Venture Capital
Private Equity

People | 5 July 2013

Bharat Rawla Joins Macquarie Securities India

by Tilak Devadiga
Bharat Rawla Joins Macquarie Securities India
Share on Social Media Email Facebook Twitter Linkedin

Macquarie Securities has appointed ex MD of Morgan Stanley as the MD and head of Macquarie Securities India.

Bharat gets with him more than 12 years of experience from Morgan Stanley where he had worked in both London and Mumbai, leading teams and building businesses within the equity and fixed income divisions.

Prior to this, Bharat held positions within the research and sales teams of Lehman Brothers in London and New York.

Having a bachelor’s degree from Illinois Wesleyan University, he also holds MBA from UNC Kenan-Flagler Business School.

Macquarie Securities is a part of the Macquarie Securities Group (MSG) which is a global institutional securities house with strong Asia-Pacific foundations covering sales, research, ECM, execution and derivatives activities. It is a full-service institutional cash equities broker in Australia, Asia, South Africa and Canada with offerings in the US and Europe, and retail derivatives in key locations globally.

In India Macquarie started operations in 2005 and provides specialist investment, advisory and financial services.

In July 2004, Macquarie acquired ING’s Asian equity businesses involving sales trading execution, research and facilitation trading. The restructured businesses operates as Macquarie Securities in 11 locations within Asia.

Earlier this year, IDFC had appointed Sandeep Gupta as MD of Corporate Finance Division of @IDFC_Capital_L. Also, @KPMG has appointed Utkarsh Palnitkar as Partner and National Head of Transactions and Restructuring Practice in India

Rakesh Jhunjhunwala Buys Stake In Firstsource Solutions

Rakesh Jhunjhunwala Buys Stake In Firstsource Solutions

Rakesh Jhunjhunwala bought 25 Mn shares of Firstsource Solutions on NSE through a bulk deal transaction amounting to R25 Cr from ICICI and others.This transaction gives Jhunjhunwala a 3.8% stake in the company.


Glenmark Pharma Plans Fund Raise

Glenmark Pharma Plans Fund Raise

BSE listed Glenmark Pharmaceutical has sought the board approval to raise $300 Mn (c.INR 18 Bn) by issuing equity or equity linked securities by way of QIP.

DealCurry Timeline
TL Home Search New Keet
A 314, 3rd Floor, AntopHill Warehousing Company,
Near Dosti Acres
Mumbai 400037
Copyright © EagleEye Research & Media Pvt. Ltd. 2009 All Rights Reserved - Interactive multimedia analysis platform for financial markets.
Site map |Terms of Use |Privacy Policy
DealCurry tracks financial and corporate markets for events, interprets and integrates the information in our platform, providing premium data, news and analytics. DealCurry provides comprehensive coverage of the capital markets through an intuitive, user-friendly interface.